文献速递腹部介入USCTMR

消融前三维超声可预测肝细胞癌射频消融术后的治疗效果及局部肿瘤进展

Preablation three-dimensional ultrasonography can predict therapeutic effect and local tumor progression after radiofrequency ablation for hepatocellular carcinoma.
PubMed 文献 · Eur J Radiol · 2020-10-17

本研究纳入60例患者共73个肝细胞癌结节,在电极穿刺后、消融前采集三维超声数据,以预测消融边缘(AM)。48个结节(66%)可在C平面显示,其中39个(81%)预测与实测AM一致。预测AM(+)者局部肿瘤进展率显著低于AM(-)者(p=0.03),预测AM≥3 mm者亦显著低于<3 mm者(p=0.04)。结论认为三维超声可在射频消融前预测AM。

要点

  • 消融前三维超声可在C平面预测消融边缘,48个可显示结节中81%与消融后CT/MR实测AM一致。
  • 预测AM(+)结节局部进展率7%(3/43),显著低于AM(-)的40%(2/5)(p=0.03)。
  • 预测AM≥3 mm的21个结节均无局部进展,进展率显著低于AM<3 mm者(p=0.04)。

核心结论

  • 三维超声可在射频消融前预测消融边缘,预测AM(+)及AM≥3 mm者局部肿瘤进展率显著更低。

研究设计与样本

  • 研究纳入60例患者共73个肝细胞癌结节,于电极穿刺后、消融前采集三维超声数据。
  • 以消融后CT/MR图像测量的消融边缘为参考,比较预测AM与实测AM的一致性。

关键影像表现/征象

  • 73个结节中48个(66%)可在垂直于电极的C平面显示,并用于预测AM。
  • 48个可显示结节中39个(81%)预测AM与消融后CT/MR实测AM一致。

诊断标准与关键数值

  • 预测AM定义为「0.5b - a」,其中a为C平面上电极至肿瘤边缘的最大距离,b为消融区直径。
  • 「0.5b - a」≥0 mm为AM(+),<0 mm为AM(-);另以≥3 mm与<3 mm分组。
  • 预测AM(+)结节局部进展3/43(7%),AM(-)结节2/5(40%),差异显著(p=0.03)。
  • 预测AM≥3 mm的21个结节均无局部进展,AM<3 mm者进展率显著更高(p=0.04)。
  • 消融后CT/MR实测AM≥0 mm者局部进展2/42(4.7%),<0 mm者5/6(83.3%),差异显著(p=0.0008)。

临床应用与阅片要点

  • 消融前三维超声可在C平面预测消融边缘,预测AM(+)及AM≥3 mm者局部肿瘤进展率更低。
  • 预测AM(-)结节局部进展率达40%(2/5),消融后CT/MR实测AM<0 mm者达83.3%(5/6)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

PURPOSE: To assess the agreement between ablative margin (AM) predicted by preablation three-dimensional ultrasonography (3D-US) and AM measured on postablation computed tomography (CT)/magnetic resonance (MR) images.

METHODS: Sixty patients with 73 hepatocellular carcinoma nodules were enrolled. 3D-US data were collected immediately after puncture by the electrode before ablation. The maximum distance from the electrode to the edge of the tumor in the plane perpendicular to the electrode (C-plane) was defined as "a" and the diameter of the ablation zone as "b". We classified predicted AM into "0.5b - a" ≥0 mm as AM(+) or <0 mm as AM(-), and "0.5b - a" ≥3 mm or <3 mm.

RESULTS: Forty-eight nodules (66 %) were visualized in the C-plane. There was an agreement between the predicted and measured AMs for 39 (81 %) of the 48 nodules. Local tumor progression was observed in 3 (7%) of 43 nodules with predicted AM(+) and in 2 (40 %) of 5 nodules with predicted AM(-) but was not observed in any of 21 nodules with predicted AM ≥ 3 mm. The local tumor progression rate was significantly lower for nodules with predicted AM(+) compared with predicted AM(-)(p = 0.03), and for nodules with predicted AM ≥ 3 mm compared with predicted AM < 3 mm (p = 0.04). Local progression was detected in 2 (4.7 %) of 42 nodules with a sufficient AM (≥0 mm) on postablation CT/MR images and in 5 (83.3 %) of 6 nodules with an insufficient AM (<0 mm); the difference in progression rate was significant (p = 0.0008).

CONCLUSION: 3D-US allows prediction of the AM before radiofrequency ablation.

来源:Eur J Radiol,查看原文。版权归原作者所有。

引用

  1. Matsuki Y, Matono T, Koda M, et al. Preablation three-dimensional ultrasonography can predict therapeutic effect and local tumor progression after radiofrequency ablation for hepatocellular carcinoma. Eur J Radiol. 2020. PMID: 33126170. doi:10.1016/j.ejrad.2020.109358

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。